Clearmind Medicine (CMND) 6-K 17 Mar 23 Condensed Interim Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Jan. 31, 2023
Document Information Line Items
Entity Registrant Name	Clearmind Medicine Inc.
Document Type	6-K
Current Fiscal Year End Date	--10-31
Amendment Flag	false
Entity Central Index Key	0001892500
Document Period End Date	Jan. 31, 2023
Entity File Number	001-41557

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - CAD ($)	Jan. 31, 2023	Oct. 31, 2022
Current assets
Cash and cash equivalents	$ 4,498,048	$ 175,768
Other receivables	291,829	69,518
Short-term investment (Note 3)	180,225	264,449
Prepaid expenses	933,829	19,443
Related parties (Note 4b)	77,314	64,134
Total current assets	5,981,245	593,312
Non-current assets
Property and equipment	15,012	17,610
Intangible assets	173,840	177,797
Restricted cash	20,000	20,000
Right-of-use asset	24,340	48,768
Deferred offering costs (Note 5c)		270,487
Total non-current assets	233,192	534,662
Total assets	6,214,437	1,127,974
Current liabilities
Accounts payable and accrued liabilities	900,872	1,906,706
Due to related parties (Note 4)	143,832	281,844
Derivative liability (Note 5c(i))		396,597
Lease liability	27,017	52,399
Total liabilities	1,071,721	2,637,546
Shareholders’ equity (deficit)
Share capital and share premium (Note 5)	17,691,059	9,153,900
RSU reserve (Note 8)	742,662	672,945
Warrants (Note 6)	1,003,801	626,641
Share-based payment reserve (Note 7)	2,048,233	1,915,895
Accumulated other comprehensive loss	(33,622)	(29,004)
Accumulated deficit	(16,309,417)	(13,849,949)
Total shareholders’ equity (deficit)	5,142,716	(1,509,572)
Total liabilities and shareholders’ equity (deficit)	$ 6,214,437	$ 1,127,974

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - CAD ($)		3 Months Ended
		Jan. 31, 2023	Jan. 31, 2022
Operating expenses
General and administrative		$ 1,679,546	$ 1,660,157
Research and development		792,460	424,262
Total operating expenses		2,472,006	2,084,419
Loss before other expenses		(2,472,006)	(2,084,419)
Finance expenses
Unrealized loss on short-term investment (Note 3)		(84,224)
Foreign exchange gain (loss)		42,348	(6,464)
Interest income		36,875
Total finance expenses		(5,001)	(6,464)
Other income
Dividend received		22,101
Total other incomes		22,101
Loss before taxes		(2,454,906)	(2,090,883)
Tax expenses		(4,562)
Net Loss		(2,459,468)	(2,090,883)
Other comprehensive loss for the period
Items that may be reclassified subsequently to profit or loss:
Foreign exchange differences on translation of foreign operations		(4,618)
Comprehensive loss		$ (2,464,086)	$ (2,090,883)
Loss per share, basic (in Dollars per share)	[1]	$ (1.07)	$ (1.67)
Weighted average number of shares for the purposes of basic loss per share (in Shares)	[1]	2,297,738	1,251,790
[1] On September 30, 2022, the Company effected a 1-for-30 share consolidation (reverse share split) of its issued and outstanding shares. All share amounts have been retroactively restated for all periods presented.

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares		3 Months Ended
		Jan. 31, 2023	Jan. 31, 2022
Statement of cash flows [abstract]
Loss per share, diluted	[1]	$ (1.07)	$ (1.67)
Weighted average number of shares for the purposes of diluted loss per share	[1]	2,297,738	1,251,790
[1] On September 30, 2022, the Company effected a 1-for-30 share consolidation (reverse share split) of its issued and outstanding shares. All share amounts have been retroactively restated for all periods presented.

Condensed Interim Statements of

Condensed Interim Statements of Changes in Shareholders' Equity (Deficit) - CAD ($)		Share capital and share premium	RSU and share reserve	Warrants	Share-based payment reserve	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Oct. 31, 2021		$ 7,905,514	$ 154,000	$ 342,000	$ 839,457		$ (4,439,143)	$ 4,801,828
Balance (in Shares) at Oct. 31, 2021	[1]	1,250,833
Shares issuable for vested RSU’s			36,000					36,000
Shares issued and issuable for services		$ 28,800	73,003					101,803
Shares issued and issuable for services (in Shares)	[1]	1,333
Share-based compensation					218,974			218,974
Net loss for the period							(2,090,883)	(2,090,883)
Balance at Jan. 31, 2022		$ 7,934,314	263,003	342,000	1,058,431		(6,530,026)	3,067,722
Balance (in Shares) at Jan. 31, 2022	[1]	1,252,166
Balance at Oct. 31, 2022		$ 9,153,900	672,945	626,641	1,915,895	(29,004)	(13,849,949)	(1,509,572)
Balance (in Shares) at Oct. 31, 2022	[1]	1,319,770
Share-based compensation					132,338			132,338
Net loss for the period							(2,459,468)	(2,459,468)
Foreign currency translation gain						(4,618)		(4,618)
Total comprehensive loss for the period						(4,618)	(2,459,468)	(2,464,086)
Public offering (Note 5c(i))		$ 8,089,751		376,851				8,466,602
Public offering (Note 5c(i)) (in Shares)	[1]	1,153,847
Shares and warrants issuable to Medigus (Note 5c(i))		$ 396,288		309				396,597
Shares issued from RSUs (Note 5c(ii))		$ 51,120	(51,120)
Shares issued from RSUs (Note 5c(ii)) (in Shares)	[1]	4,824
Shares for services (Notes 11a, 11c)			46,832					46,832
RSU’s vested (Note 8(i))			74,005					74,005
Balance at Jan. 31, 2023		$ 17,691,059	$ 742,662	$ 1,003,801	$ 2,048,233	$ (33,622)	$ (16,309,417)	$ 5,142,716
Balance (in Shares) at Jan. 31, 2023	[1]	2,478,441
[1] On September 30, 2022, the Company effected a 1-for-30 share consolidation (reverse share split) of its issued and outstanding shares. All share amounts have been retroactively restated for all periods presented.

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - CAD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Statement of cash flows [abstract]
Net loss	$ (2,459,468)	$ (2,090,883)
Adjustments for:
Amortization of intangible assets	3,957	10,102
Amortization of right-of-use asset	18,399
Interest on lease liability	2,324
Dividend received	22,101
Depreciation of property and equipment	2,607	2,040
Share-based compensation	253,175	356,777
Unrealized loss on short-term investment	84,224
Tax expenses	4,562
Movements in working capital:
Decrease (increase) in amounts receivable	(257,592)	37,821
Decrease (increase) in prepaid expenses	(914,386)	62,634
Decrease in accounts payable and accrued liabilities	(739,909)	(202,805)
Increase (decrease) in due to related parties	(138,012)	37,459
Net cash used in operating activities	(4,118,018)	(1,786,855)
Financing activities
Proceeds from issuance of shares, net (Note 5c(i))	8,466,602
Repayment of lease liabilities	(21,281)
Net cash provided by financing activities	8,445,321
Effect of foreign exchange rate changes	(5,023)	(404)
Net increase (decrease) in cash and cash equivalents	4,322,280	(1,787,259)
Cash and cash equivalents at beginning of period	175,768	4,599,437
Cash and cash equivalents at end of period	4,498,048	2,812,178
Supplementary disclosure of cash flow information:
Cash received for interest	36,875
Non-cash financing and investing activities
Derivative liability converted to equity (Note 5c(i))	$ 396,597

Nature of Operations and Going

Nature of Operations and Going Concern	3 Months Ended
	Mar. 31, 2023
Description Of Nature Of Entitys Operations And Principal Activities Abstract
Nature of Operations and Going Concern	1.Nature of Operations and Going Concern   a.Clearmind Medicine Inc. (formerly Cyntar Ventures Inc.) (the “Company”) was incorporated in the province of British Columbia on July 18, 2017. The Company changed its name from Cyntar Ventures Inc. to Clearmind Medicine Inc. on March 24, 2021. The Company’s previous business was carrying out mining exploration operations and was involved in the exploration of the Lorn mineral property located in the Clinton and Lillooet Mining Divisions of British Columbia. Effective May 18, 2021, the Company is in the business of researching, developing and marketing proprietary formulations of psychedelic designer therapeutics with an initial focus of developing products. The Company’s head office is located at Suite 101, 1220 West 6th Avenue, Vancouver, BC, V6H 1A5. The Company’s Israeli subsidiary (Clearmindmed Ltd.) provides research and development services to the Company.  On November 14, 2022, the Company completed a public offering for aggregate gross proceeds of US$7.5 million and up listing to the Nasdaq Capital Market (“Nasdaq”), see note 5c. The Company trades under the symbol CMND on both the Nasdaq and the Canadian Securities Exchange (“CSE”) in Toronto.  b.Going concern  These condensed interim consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. For the three months ended January 31, 2023, the Company has not generated any revenues and has negative cash flow from operations of $4,118,018. As of January 31, 2023, the Company has an accumulated deficit of $16,309,417. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors may cast substantial doubt on the Company’s ability to continue as a going concern. These condensed interim consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.  c.Reverse share split  On September 30, 2022, the Company’s Board of Directors approved a 1-for-30 reverse split of its issued and outstanding ordinary shares, effective as of September 30, 2022, pursuant to which holders of the Company’s ordinary shares received 0.0333 of an ordinary share for every one ordinary share. All issued and outstanding ordinary shares or instruments convertible into ordinary shares contained in these financial statements have been retroactively adjusted to reflect the reverse share split for all periods presented, unless explicitly stated otherwise.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Jan. 31, 2023
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies a. Basis of Presentation The accompanying condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Ltd. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in Canadian dollars, which is the Company’s functional currency. b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2022 and the notes thereto (the “2022 Annual Report”). The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the three months ended January 31, 2023 are not necessarily indicative of the results for the year ending October 31, 2023, or for any future period. As of January 31, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report. c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions may cast significant doubt upon the Company’s ability to continue as a going concern.

Short-term Investment

Short-term Investment	3 Months Ended
	Jan. 31, 2023
Short Term Investment Abstract
Short-term Investment	3. Short-term Investment As of January 31, 2023, the Company holds 27,778 common shares of Medigus Ltd (“Medigus”) (approximately 0.11%) with a total fair value of $180,225. The fair value of common shares held was determined by reference to public price quotations in an active market. October 31, Additions Unrealized January 31, Medigus Ltd. – Shares $ 264,449 $ - $ (84,224 ) $ 180,225

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Disclosure Of Related Party Text Block Abstract
Related Party Transactions	4. Related Party Transactions a. Compensation to key management personnel (i) The compensation to key management personnel for employment services they provide to the Company is as follows: Three months ended Three months ended January 31, January 31, 2023 2022 Officers: Consulting fees $ 190,374 $ 127,859 Share based compensation 59,933 147,424 $ 250,307 $ 275,283 Directors: Directors’ fees $ 73,581 $ 24,000 Share based compensation 59,465 14,979 $ 133,046 $ 38,979 (ii) Balances with related parties January 31, October 31, 2023 2022 Amounts owed to officers $ 124,257 $ 185,830 Amounts owed to directors 19,575 96,014 $ 143,832 $ 281,844 b. On March 7, 2022, the Company signed an agreement with SciSparc, pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc, which may have similar or different objectives than the Company’s. Such activities could detract from the time these people have to allocate to the Company’s affairs. To date, no determination has been made to pursue the joint venture and the development of the research activities with SciSparc remains in a very early stage. For the three months ended January 31, 2023, the Company received $13,180 as a reimbursement for research and development expenses conducted within the framework of the Cooperation Agreement. As of January 31, 2023, $77,314 is owed to the Company. c. The Company shares office space with SciSparc.

Share Capital

Share Capital	3 Months Ended
	Jan. 31, 2023
Disclosure of Share Capital [Abstract]
Share Capital	5. Share Capital a. The Company’s authorized share capital is unlimited common shares without par value share. As of January 31, 2023, the number of shares issued and outstanding are 2,478,441 (October 31, 2022 - 1,319,770). b. On September 30, 2022, the Company effected a 1-for-30 share consolidation (reverse share split) of its issued and outstanding shares. All share amounts and instruments convertible into shares have been retroactively restated for all periods presented. c. Share transactions during the three months ended January 31, 2023: (i) On November 14, 2022, the Company completed an underwritten public offering of 1,153,847 shares at a price to the public of US$6.50 per share (CAD$8.65), for aggregate gross proceeds of US$7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds received were $8,466,602. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 173,077 additional common shares, equal to 15% of the number of shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been US$6.50 per share (CAD$8.65). The Over-Allotment was not exercised. Aegis received 57,692 underwriter warrants, each such warrant entitling the agents to receive one common share upon payment of US $8.125 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value for underwriter warrants total of $376,851 and have been credited to the warrant reserve. The fair value has been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 107 % In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq under the symbol “CMND” on November 15, 2022. Following the public offering, Medigus were entitled to receive 44,829 shares and 2,241 warrants pursuant to an anti-dilution clause included in the agreement signed between the Company and Medigus on June 29, 2022. The anti-dilution feature was recorded as a derivative liability as of October 31, 2022 and has been classified to equity upon completion of the IPO. (ii) On January 16, 2023, 4,824 shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $51,120 at the time of issuance. (iii) During the three months ended January 31, 2023, pursuant to existing commitments detailed in notes 11c and 11a, the Company is committed to issue 9,386 shares with a fair value of $46,832 to two service providers. As of the date of this report, these shares have not been issued. d. Share transactions during the three months ended January 31, 2022: On November 26, 2021, the Company issued 1,333 common shares with a fair value of $28,800. The amount is in respect of services provided by the Chief Scientific Officer in prior periods (Note 11(a)) and therefore the amounts has been reclassified from RSU reserve to Share Premium.

Share Purchase Warrants

Share Purchase Warrants	3 Months Ended
	Jan. 31, 2023
Share Purchase Warrants [Abstract]
Share Purchase Warrants	6. Share Purchase Warrants The following table summarizes the continuity of the Company’s share purchase warrants: Number of Weighted Balance, October 31, 2021 and January 31, 2022 526,666 $ 21.84 Issued 66,245 60.00 Balance, October 31, 2022 592,911 26.10 Issued (note 5c(i)) 57,692 10.85 Balance, January 31, 2023 650,603 $ 24.75 As of January 31, 2023, the following share purchase warrants were outstanding: Number of Exercise price Expiry date 250,000 $ 4.50 April 22, 2024 276,666 $ 37.50 December 22, 2022 66,245 $ 60.00 August 14, 2023 57,692 $ 10.85 (*) November 17, 2027 650,603 (*) Exercise price is USD$8.125.

Stock Options

Stock Options	3 Months Ended
	Mar. 31, 2023
Stock Options Abstract
Stock Options	7. Stock Options On September 1, 2021, the Company implemented a stock option plan pursuant to which stock options may be granted to directors, officers, employees, and consultants of the Company. The Board of directors is authorized to grant the maximum number of common shares reserved for issuance in any 12-month period to anyone, optionee, other than a consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant. The maximum number of common shares reserved for issuance in any 12-month period to any consultant may not exceed 2% of the issued and outstanding common shares at the date of the grant and the maximum number of common shares reserved for issuance in any 12-month period to all persons engaged in investor relations activities may not exceed 2% of the issued and outstanding number of common shares at the date of the grant. The following table summarizes the continuity of the Company’s stock options: Number Weighted Outstanding, October 31, 2021 111,889 $ 20.67 Granted (i) 86,333 20.68 Cancelled (ii) (40,556 ) 21.56 Outstanding, October 31, 2022 and January 31, 2023 157,666 $ 20.45 Exercisable, January 31, 2023 82,389 $ 20.33 Additional information regarding stock options outstanding as of January 31, 2023, is as follows: Outstanding Exercisable Range of Number of Weighted Weighted Number of Weighted $ 5.55 16,000 3.32 $ 5.55 8,000 $ 5.55 $ 16.80 29,333 9.01 16.80 14,389 16.80 $ 20.40 12,667 8.86 20.40 12,667 20.40 $ 22.50 35,000 3.31 22.50 18,750 22.50 $ 23.40 6,000 6.24 23.40 2,750 23.40 $ 24.00 31,333 9.01 24.00 10,444 24.00 $ 24.90 4,000 3.64 24.90 4,000 24.90 $ 25.20 20,000 3.42 25.20 10,000 25.20 $ 30.00 3,333 8.86 30.00 1,389 30.00 157,666 6.20 $ 20.45 82,389 $ 20.33 The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: 2023 2022 Risk-free interest rate 2.60%-2.72 % 1.58 % Expected life (in years) 5.38 5.91 Expected volatility 91.81%-94.66 % 94 % The portion of the total fair value of stock options expensed during the three months ended January 31, 2023, was $132,338 (2022 - $218,974) which was recorded as share-based payment reserve and charged to operations. The weighted average fair value of stock options granted during the three months ended January 31, 2023 was $3.02 per share (no options were granted during the three months ended January 31, 2023).

Restricted Share Units

Restricted Share Units	3 Months Ended
	Jan. 31, 2023
Schedule of Restricted Share Units [Abstract]
Restricted Share Units	8. Restricted Share Units On August 4, 2021, the Company approved an RSU plan, which is designed to provide certain directors, officers, employees, and consultants of the Company with the opportunity to acquire RSU’s of the Company. Each unit is equivalent in value to a common share and upon vesting results in the holder thereof being issued, at the discretion of the Board, either (i) a common share, or (ii) an amount of cash equal to the fair market value of a common share. During the three months ended January 31, 2023, the Company recognized RSU reserve of $466,314 (2021 - $190,000) related to vested RSU’s. The following table summarizes the continuity of RSUs: Number of Weighted Balance, October 31, 2021 – $ – Granted 35,328 10.55 Vested (35,328 ) 10.55 Balance, October 31, 2022 – $ – Granted (i) 14,774 5.01 Vested (14,774 ) 5.01 Balance, January 31, 2023 – $ – (i) During the three months ended January 31, 2023, the Company issued 14,774 RSU’s with a fair value of $74,005 to consultants.

Financial Instruments and Risk

Financial Instruments and Risk Management	3 Months Ended
	Jan. 31, 2023
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	9. Financial Instruments and Risk Management Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of January 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 180,225 $ – $ – $ 180,225 Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2022, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 264,449 $ – $ – $ 264,449 Derivative liability – 396,597 – 396.597 The fair value of other assets and liabilities, which include cash, amounts receivable, accounts payable and accrued liabilities, and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments. b. Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and other receivables. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure. c. Foreign Exchange Rate Risk Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in NIS and U.S dollars. The Company has not entered into foreign exchange rate contracts to mitigate this risk. The following table indicates the impact of foreign currency exchange risk on net working capital as of January 31, 2023. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of January 31, 2023. Cash $ 4,491,696 Amounts receivable 161,758 Accounts payable and accrued liabilities (888,123 ) Due to related parties (112,957 ) Total foreign currency financial assets and liabilities $ 3,652,374 Impact of a 10% strengthening or weakening of foreign exchange rate $ 365,237 d. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates. e. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner. The following amounts are the contractual maturities of financial liabilities as of January 31, 2023 and October 31, 2022: January 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 900,872 $ 900,872 $ – Due to related parties 143,832 143,832 – Lease liability 27,017 27,017 – $ 1,071,721 $ 1,071,721 $ – October 31, 2022 Total Within Within Accounts payable and accrued liabilities $ 1,906,706 $ 1,906,706 $ – Due to related parties 281,844 281,844 – Derivative liability 396,597 396,597 Lease liability 52,399 52,399 $ 2,637,546 $ 2,637,546 $ –

Capital Management

Capital Management	3 Months Ended
	Jan. 31, 2023
Disclosure Of Capital Management Abstract
Capital Management	10. Capital Management The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital, RSU reserve, warrants reserve, and options reserve. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the three months ended January 31, 2023.

Commitments

Commitments	3 Months Ended
	Jan. 31, 2023
Commitments [Abstract]
Commitments	11. Commitments a. On November 1, 2020 (as amended on May 12, 2021), the Company entered into an agreement to acquire the rights, title, and interest in certain patents and patent applications in exchange for entering into a consulting services agreement with the consultant. The consultant will become the Company’s scientific consultant and will be compensated with a monthly fee of $5,000 starting on February 1, 2021. The Company is to issue the consultant 16,000 common shares in equal instalments, at the end of each quarter, commencing with the ending of the first complete quarter after the date on which the Canadian Securities Exchange (“Listing Date”) has provided its final approval to the Company’s change of business, over a period of three years. The Company is to also grant the consultant 16,000 stock options which will be exercisable at $5.55 per common share (granted). The stock options will vest in equal parts at the end of each quarter commencing with the ending of the first complete quarter after the Listing Date, over a period of three years. During the three months ended January 31, 2023, the Company recognized share-based compensation of $6,549 (2021 - $ nil nil . b. Effective January 1, 2022, the Company entered into advisory agreements with three advisors of the Company, whereby the Company agreed to issue each consultant 666 RSU’s at the end of each month commencing January 31, 2022, for an initial term of 12 months. During the three months ended January 31, 2023, the Company recognized share-based compensation of $30,280 related to RSU’s. As of January 31, 2023, a total of 26,000 shares are issuable to the 3 advisors in consideration for 13 months of services. c. On March 1, 2022, the Company entered into an advisory agreement with a consultant, whereby the Company agreed to pay the consultant ILS 20,000 ($7,752) and 666 RSU’s per month for a period of 12 months. During the three months ended January 31, 2023, the Company recognized share-based compensation of $10,093 related to RSU’s. As of January 31, 2023, a total of 7,333 shares are issuable to the advisor in consideration for 11 months of services. d. On March 14, 2022, the Company entered an agreement with a consultant, whereby the Company agreed to issue the consultant RSU’s equivalent to US$10,000 per month for a period of three months. The term is automatically renewed unless terminated by the Company with three days’ written notice within the initial term or thirty days in a subsequent term. From January 1, 2023, the agreement was amended to $5,000 per month. His agreement is still in effect. During the three months ended January 31, 2023, the Company recognized share-based compensation of $33,631 related to RSU’s. As of January 31, 2023, a total of 6,774 shares are issuable to the advisor in consideration for 10 months of services. e. On May 23, 2022, the Company entered an agreement with a consultant, whereby the Company agreed to issue the consultant RSU’s equivalent to US$10,000 per month for a period of three months. The term is automatically renewed unless terminated by the Company with three days’ written notice within the initial term or thirty days in a subsequent term. During the three months ended January 31, 2023, the Company recognized share-based compensation of $40,283 related to RSU’s.

Segmented Information

Segmented Information	3 Months Ended
	Jan. 31, 2023
Segmented Information [Abstract]
Segmented Information	12. Segmented Information As of January 31, 2023, the Company has one operating segment, research and development of psychedelic medicine, which takes place primarily in Israel. The Company’s non-current assets by geographical location are as follows: January 31, 2023 Canada United Europe Asia Total Intangible assets $ – $ 52,152 $ 52,152 $ 69,536 $ 173,840 Property and equipment – – – 15,012 15,012 Restricted cash 20,000 – – – 20,000 ROU asset – – – 24,340 24,340 $ 20,000 $ 52,152 $ 52,152 $ 108,888 $ 233,192 October 31, 2022 Canada United Europe Asia Total Intangible assets $ – $ 53,339 $ 53,339 $ 71,119 $ 177,797 Property and equipment – – – 17,610 17,610 Restricted cash 20,000 – – – 20,000 ROU asset – – – 48,768 48,768 Deferred offering costs – 270,487 – – 270,768 $ 20,000 $ 323,826 $ 53,339 $ 137,497 $ 534,662

Subsequent Events

Subsequent Events	3 Months Ended
	Jan. 31, 2023
Disclosure Of Events After Reporting Period Text Block Abstract
Subsequent Events	13. Subsequent Events On February 22, 2023, 12,006 shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $141,071 at the time of issuance.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Ltd. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in Canadian dollars, which is the Company’s functional currency.
Unaudited Interim Financial Information	b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2022 and the notes thereto (the “2022 Annual Report”). The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the three months ended January 31, 2023 are not necessarily indicative of the results for the year ending October 31, 2023, or for any future period. As of January 31, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.
Significant Accounting Estimates and Judgments	c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions may cast significant doubt upon the Company’s ability to continue as a going concern.

Short-term Investment (Tables)

Short-term Investment (Tables)	3 Months Ended
	Jan. 31, 2023
Short Term Investment Abstract
Schedule of fair value common shares held	October 31, Additions Unrealized January 31, Medigus Ltd. – Shares $ 264,449 $ - $ (84,224 ) $ 180,225

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2023
Disclosure Of Related Party Text Block Abstract
Schedule of key management personnel for employment services	Three months ended Three months ended January 31, January 31, 2023 2022 Officers: Consulting fees $ 190,374 $ 127,859 Share based compensation 59,933 147,424 $ 250,307 $ 275,283 Directors: Directors’ fees $ 73,581 $ 24,000 Share based compensation 59,465 14,979 $ 133,046 $ 38,979
Schedule of balances with related parties	January 31, October 31, 2023 2022 Amounts owed to officers $ 124,257 $ 185,830 Amounts owed to directors 19,575 96,014 $ 143,832 $ 281,844

Share Capital (Tables)

Share Capital (Tables)	3 Months Ended
	Jan. 31, 2023
Disclosure of Share Capital [Abstract]
Schedule of the fair value has been estimated using the black-scholes	Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 107 %

Share Purchase Warrants (Tables

Share Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Share Purchase Warrants [Abstract]
Schedule of share purchase warrants	Number of Weighted Balance, October 31, 2021 and January 31, 2022 526,666 $ 21.84 Issued 66,245 60.00 Balance, October 31, 2022 592,911 26.10 Issued (note 5c(i)) 57,692 10.85 Balance, January 31, 2023 650,603 $ 24.75
Schedule of share purchase warrants were outstanding	Number of Exercise price Expiry date 250,000 $ 4.50 April 22, 2024 276,666 $ 37.50 December 22, 2022 66,245 $ 60.00 August 14, 2023 57,692 $ 10.85 (*) November 17, 2027 650,603 (*) Exercise price is USD$8.125.

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2023
Stock Options Abstract
Schedule of additional information regarding stock options outstanding	Number Weighted Outstanding, October 31, 2021 111,889 $ 20.67 Granted (i) 86,333 20.68 Cancelled (ii) (40,556 ) 21.56 Outstanding, October 31, 2022 and January 31, 2023 157,666 $ 20.45 Exercisable, January 31, 2023 82,389 $ 20.33
Schedule of additional information regarding stock options outstanding	Outstanding Exercisable Range of Number of Weighted Weighted Number of Weighted $ 5.55 16,000 3.32 $ 5.55 8,000 $ 5.55 $ 16.80 29,333 9.01 16.80 14,389 16.80 $ 20.40 12,667 8.86 20.40 12,667 20.40 $ 22.50 35,000 3.31 22.50 18,750 22.50 $ 23.40 6,000 6.24 23.40 2,750 23.40 $ 24.00 31,333 9.01 24.00 10,444 24.00 $ 24.90 4,000 3.64 24.90 4,000 24.90 $ 25.20 20,000 3.42 25.20 10,000 25.20 $ 30.00 3,333 8.86 30.00 1,389 30.00 157,666 6.20 $ 20.45 82,389 $ 20.33
Schedule of estimated using the Black-Scholes option pricing model assuming no expected dividends	2023 2022 Risk-free interest rate 2.60%-2.72 % 1.58 % Expected life (in years) 5.38 5.91 Expected volatility 91.81%-94.66 % 94 %

Restricted Share Units (Tables)

Restricted Share Units (Tables)	3 Months Ended
	Jan. 31, 2023
Restricted Share Units [Abstract]
Schedule of restricted share units	Number of Weighted Balance, October 31, 2021 – $ – Granted 35,328 10.55 Vested (35,328 ) 10.55 Balance, October 31, 2022 – $ – Granted (i) 14,774 5.01 Vested (14,774 ) 5.01 Balance, January 31, 2023 – $ – (i) During the three months ended January 31, 2023, the Company issued 14,774 RSU’s with a fair value of $74,005 to consultants.

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	3 Months Ended
	Jan. 31, 2023
Financial Instruments and Risk Management [Abstract]
Schedule of assets and liabilities measured at fair value	Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 180,225 $ – $ – $ 180,225 Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 264,449 $ – $ – $ 264,449 Derivative liability – 396,597 – 396.597
Schedule of foreign currency exchange risk on net working capital	Cash $ 4,491,696 Amounts receivable 161,758 Accounts payable and accrued liabilities (888,123 ) Due to related parties (112,957 ) Total foreign currency financial assets and liabilities $ 3,652,374 Impact of a 10% strengthening or weakening of foreign exchange rate $ 365,237
Schedule of contractual maturities of financial liabilities	January 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 900,872 $ 900,872 $ – Due to related parties 143,832 143,832 – Lease liability 27,017 27,017 – $ 1,071,721 $ 1,071,721 $ – October 31, 2022 Total Within Within Accounts payable and accrued liabilities $ 1,906,706 $ 1,906,706 $ – Due to related parties 281,844 281,844 – Derivative liability 396,597 396,597 Lease liability 52,399 52,399 $ 2,637,546 $ 2,637,546 $ –

Segmented Information (Tables)

Segmented Information (Tables)	3 Months Ended
	Jan. 31, 2023
Segmented Information [Abstract]
Schedule of company’s non-current assets by geographical location	January 31, 2023 Canada United Europe Asia Total Intangible assets $ – $ 52,152 $ 52,152 $ 69,536 $ 173,840 Property and equipment – – – 15,012 15,012 Restricted cash 20,000 – – – 20,000 ROU asset – – – 24,340 24,340 $ 20,000 $ 52,152 $ 52,152 $ 108,888 $ 233,192 October 31, 2022 Canada United Europe Asia Total Intangible assets $ – $ 53,339 $ 53,339 $ 71,119 $ 177,797 Property and equipment – – – 17,610 17,610 Restricted cash 20,000 – – – 20,000 ROU asset – – – 48,768 48,768 Deferred offering costs – 270,487 – – 270,768 $ 20,000 $ 323,826 $ 53,339 $ 137,497 $ 534,662

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) $ / shares in Units, $ in Millions				3 Months Ended
	Nov. 14, 2022 CAD ($)	Nov. 14, 2022 USD ($)	Sep. 30, 2022 $ / shares	Jan. 31, 2023 CAD ($)	Oct. 31, 2022 CAD ($)
Nature of Operations and Going Concern (Details) [Line Items]
Aggregate gross proceeds		$ 7.5
Accumulated deficit				$ (16,309,417)	$ (13,849,949)
Ordinary per share (in Dollars per share) | $ / shares			$ 0.0333
Nasdaq [Member]
Nature of Operations and Going Concern (Details) [Line Items]
Aggregate gross proceeds	$ 7,500,000
Going Concern [Member]
Nature of Operations and Going Concern (Details) [Line Items]
Negative cash flow from operations				4,118,018
Accumulated deficit				$ 16,309,417

Significant Accounting Polici_2

Significant Accounting Policies (Details)	3 Months Ended
	Jan. 31, 2023
Disclosure Of Significant Accounting Policies Text Block Abstract
Owned subsidiary percentage	100%

Short-term Investment (Details)

Short-term Investment (Details)	Jan. 31, 2023 CAD ($) shares
Short-term Investment (Details) [Line Items]
Common shares	14,774
Shares rate	0.11%
Total fair value | $	$ 180,225
Medigus Ltd [Member]
Short-term Investment (Details) [Line Items]
Common shares	27,778

Short-term Investment (Detail_2

Short-term Investment (Details) - Schedule of fair value common shares held - Medigus Ltd [Member]	3 Months Ended
	Jan. 31, 2023 CAD ($) shares
Short-term Investment (Details) - Schedule of fair value common shares held [Line Items]
Beginning shares | shares	264,449
Additions | $
Unrealized loss | $	$ (84,224)
Ending shares | shares	180,225

Related Party Transactions (Det

Related Party Transactions (Details) - CAD ($)		3 Months Ended
	Jan. 31, 2023	Jan. 31, 2023
Disclosure Of Related Party Text Block Abstract
Reimbursement for research		$ 13,180
Owed to the company	$ 77,314

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of key management personnel for employment services - CAD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Officers:
Officers management	$ 250,307	$ 275,283
Directors:
Directors employment services	133,046	38,979
Consulting Fees [Member]
Officers:
Officers management	190,374	127,859
Directors:
Directors employment services	73,581	24,000
Share Based Compensation [Member]
Officers:
Officers management	59,933	147,424
Directors:
Directors employment services	$ 59,465	$ 14,979

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of balances with related parties - CAD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Schedule Of Balances With Related Parties Abstract
Amounts owed to officers	$ 124,257	$ 185,830
Amounts owed to directors	19,575	96,014
Total amounts owed	$ 143,832	$ 281,844

Share Capital (Details)

Share Capital (Details) $ / shares in Units, $ / shares in Units, $ in Millions				1 Months Ended		3 Months Ended
		Nov. 14, 2022 CAD ($) $ / shares shares	Nov. 14, 2022 USD ($) $ / shares shares	Jan. 16, 2023 CAD ($) shares	Jun. 29, 2022 shares	Jan. 31, 2023 CAD ($) $ / shares shares	Jan. 31, 2023 CAD ($) $ / shares shares	Oct. 31, 2022 shares	Jan. 31, 2022 shares	Nov. 26, 2021 CAD ($) shares	Oct. 31, 2021 shares
Share Capital (Details) [Line Items]
Underwritten public offering		1,153,847	1,153,847
Purchase price per share | (per share)		$ 8.65	$ 6.5			$ 8.65	$ 6.5
Aggregate Gross Proceeds (in Dollars) | $			$ 7.5
Net proceeds (in Dollars) | $		$ 8,466,602
Additional common shares		173,077	173,077
Share percentage		15%	15%
Underwriter warrants						57,692
Payment per share (in Dollars per share) | $ / shares							$ 8.125
Total warrants (in Dollars) | $						$ 376,851
Share received					44,829
Shares warrant					2,241
Fair value (in Dollars) | $				$ 51,120		$ 46,832	$ 46,832			$ 28,800
Shares Issued1						9,386	9,386			1,333
Share capital and share premium [Member]
Share Capital (Details) [Line Items]
Number of shares issued						2,478,441	2,478,441	1,319,770
Number of shares outstanding	[1]					2,478,441	2,478,441	1,319,770	1,252,166		1,250,833
Restricted Share units [Member]
Share Capital (Details) [Line Items]
Exercised shares				4,824
[1] On September 30, 2022, the Company effected a 1-for-30 share consolidation (reverse share split) of its issued and outstanding shares. All share amounts have been retroactively restated for all periods presented.

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of the fair value has been estimated using the black-scholes	3 Months Ended
	Jan. 31, 2023
Schedule Of The Fair Value Has Been Estimated Using The Black Scholes Abstract
Risk-free interest rate	1.43%
Expected life (in years)	5 years
Expected volatility	107%

Share Purchase Warrants (Detail

Share Purchase Warrants (Details)	Jan. 31, 2023 $ / shares
Share Purchase Warrants [Abstract]
Exercise price	$ 8.125

Share Purchase Warrants (Deta_2

Share Purchase Warrants (Details) - Schedule of share purchase warrants - $ / shares	3 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022
Schedule of Share Purchase Warrants [Abstract]
Number of warrants, Balance beginning	592,911	526,666
Weighted average exercise price, Balance beginning	$ 26.1	$ 21.84
Number of warrants, Issued	57,692	66,245
Weighted average exercise price, Issued	$ 10.85	$ 60
Number of warrants, Balance ending	650,603	592,911
Weighted average exercise price, Balance ending	$ 24.75	$ 26.1

Share Purchase Warrants (Deta_3

Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding	3 Months Ended
	Jan. 31, 2023 $ / shares shares
Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding [Line Items]
Number of warrants outstanding	650,603
Exercise Price 4.50 [Member]
Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding [Line Items]
Number of warrants outstanding	250,000
Exercise price (in Dollars per share) | $ / shares	$ 4.5
Expiry date	Apr. 22, 2024
Exercise Price 37.50 [Member]
Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding [Line Items]
Number of warrants outstanding	276,666
Exercise price (in Dollars per share) | $ / shares	$ 37.5
Expiry date	Dec. 22, 2022
Exercise Price 60.00 [Member]
Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding [Line Items]
Number of warrants outstanding	66,245
Exercise price (in Dollars per share) | $ / shares	$ 60
Expiry date	Aug. 14, 2023
Exercise Price 10.85 [Member]
Share Purchase Warrants (Details) - Schedule of share purchase warrants were outstanding [Line Items]
Number of warrants outstanding	57,692
Exercise price (in Dollars per share) | $ / shares	$ 10.85	[1]
Expiry date	Nov. 17, 2027
[1]Exercise price is USD$8.125.

Stock Options (Details)

Stock Options (Details) - CAD ($)		3 Months Ended
	Sep. 01, 2021	Jan. 31, 2023	Jan. 31, 2022
Stock Options (Details) [Line Items]
Fair value of stock options (in Dollars)		$ 132,338	$ 218,974
Weighted average exercise price per share (in Dollars per share)		$ 3.02
Stock Options [Member]
Stock Options (Details) [Line Items]
Issued and outstanding common shares	2%
Top of Range [Member]
Stock Options (Details) [Line Items]
Issued and outstanding common shares	5%
Bottom of Range [Member]
Stock Options (Details) [Line Items]
Issued and outstanding common shares	2%

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of continuity of the company’s stock options	3 Months Ended
	Jan. 31, 2023 $ / shares shares
Schedule Of Continuity Of The Company SStock Options Abstract
Number of options Outstanding, Beginning balance | shares	111,889
Weighted average exercise price Outstanding, Beginning balance | $ / shares	$ 20.67
Number of options, Granted | shares	86,333
Weighted average exercise price, Granted | $ / shares	$ 20.68
Number of options, Cancelled | shares	(40,556)
Weighted average exercise price, Cancelled | $ / shares	$ 21.56
Number of options Outstanding, Ending balance | shares	157,666
Weighted average exercise price Outstanding, Ending balance | $ / shares	$ 20.45
Number of options Outstanding, Exercisable | shares	82,389
Weighted average exercise price Outstanding, Exercisable | $ / shares	$ 20.33

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of additional information regarding stock options outstanding	3 Months Ended
	Jan. 31, 2023 CAD ($) $ / shares shares
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Number of stock options outstanding	157,666
Weighted average remaining contractual life (years) outstanding	6 years 2 months 12 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 20.45
Number of stock options exercisable	82,389
Weighted average exercise price Exercisable (in Dollars) | $	$ 20.33
5.55 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 5.55
Number of stock options outstanding	16,000
Weighted average remaining contractual life (years) outstanding	3 years 3 months 25 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 5.55
Number of stock options exercisable	8,000
Weighted average exercise price Exercisable (in Dollars) | $	$ 5.55
16.80 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 16.8
Number of stock options outstanding	29,333
Weighted average remaining contractual life (years) outstanding	9 years 3 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 16.8
Number of stock options exercisable	14,389
Weighted average exercise price Exercisable (in Dollars) | $	$ 16.8
20.40 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 20.4
Number of stock options outstanding	12,667
Weighted average remaining contractual life (years) outstanding	8 years 10 months 9 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 20.4
Number of stock options exercisable	12,667
Weighted average exercise price Exercisable (in Dollars) | $	$ 20.4
22.50 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 22.5
Number of stock options outstanding	35,000
Weighted average remaining contractual life (years) outstanding	3 years 3 months 21 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 22.5
Number of stock options exercisable	18,750
Weighted average exercise price Exercisable (in Dollars) | $	$ 22.5
23.40 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 23.4
Number of stock options outstanding	6,000
Weighted average remaining contractual life (years) outstanding	6 years 2 months 26 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 23.4
Number of stock options exercisable	2,750
Weighted average exercise price Exercisable (in Dollars) | $	$ 23.4
24.00 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 24
Number of stock options outstanding	31,333
Weighted average remaining contractual life (years) outstanding	9 years 3 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 24
Number of stock options exercisable	10,444
Weighted average exercise price Exercisable (in Dollars) | $	$ 24
24.90 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 24.9
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years) outstanding	3 years 7 months 20 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 24.9
Number of stock options exercisable	4,000
Weighted average exercise price Exercisable (in Dollars) | $	$ 24.9
25.20 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 25.2
Number of stock options outstanding	20,000
Weighted average remaining contractual life (years) outstanding	3 years 5 months 1 day
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 25.2
Number of stock options exercisable	10,000
Weighted average exercise price Exercisable (in Dollars) | $	$ 25.2
30.00 [Member]
Stock Options (Details) - Schedule of additional information regarding stock options outstanding [Line Items]
Range of exercise prices (in Dollars per share) | $ / shares	$ 30
Number of stock options outstanding	3,333
Weighted average remaining contractual life (years) outstanding	8 years 10 months 9 days
Weighted average exercise price outstanding (in Dollars per share) | $ / shares	$ 30
Number of stock options exercisable	1,389
Weighted average exercise price Exercisable (in Dollars) | $	$ 30

Stock Options (Details) - Sch_3

Stock Options (Details) - Schedule of estimated using the Black-Scholes option pricing model assuming no expected dividends - Black-Scholes option pricing model [Member]	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Stock Options (Details) - Schedule of estimated using the Black-Scholes option pricing model assuming no expected dividends [Line Items]
Risk-free interest rate		1.58%
Expected life (in years)	5 years 4 months 17 days	5 years 10 months 28 days
Expected volatility		94%
Bottom of Range [Member]
Stock Options (Details) - Schedule of estimated using the Black-Scholes option pricing model assuming no expected dividends [Line Items]
Risk-free interest rate	2.60%
Expected volatility	91.81%
Top of Range [Member]
Stock Options (Details) - Schedule of estimated using the Black-Scholes option pricing model assuming no expected dividends [Line Items]
Risk-free interest rate	2.72%
Expected volatility	94.66%

Restricted Share Units (Details

Restricted Share Units (Details) - CAD ($)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2021
Restricted Share Units [Abstract]
RSU reserve	$ 466,314	$ 190,000
Share issued (in Shares)	14,774
Fair value amount	$ 74,005

Restricted Share Units (Detai_2

Restricted Share Units (Details) - Schedule of restricted share units - $ / shares	3 Months Ended		12 Months Ended
	Jan. 31, 2023		Oct. 31, 2022
Schedule of Restricted Share Units [Abstract]
Number of RSUs, Beginning balance
Weighted average issue price, Beginning balance
Number of RSUs, Granted	14,774	[1]	35,328
Weighted average issue price, Granted	$ 5.01	[1]	$ 10.55
Number of RSUs, Vested	(14,774)		(35,328)
Weighted average issue price, Vested	$ 5.01		$ 10.55
Number of RSUs, Ending balance
Weighted average issue price, Ending balance
[1]During the three months ended January 31, 2023, the Company issued 14,774 RSU’s with a fair value of $74,005 to consultants.

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details)	3 Months Ended
	Jan. 31, 2023
Financial Instruments and Risk Management [Abstract]
Foreign currency, percentage	10%

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Details) - Schedule of assets and liabilities measured at fair value - CAD ($)	Jan. 31, 2023	Oct. 31, 2022
Financial Instruments and Risk Management (Details) - Schedule of assets and liabilities measured at fair value [Line Items]
Short-term investment	$ 180,225	$ 264,449
Derivative liability		396.597
Fair Value Measurements Using Quoted prices in active markets for identical instruments (Level 1) [Member]
Financial Instruments and Risk Management (Details) - Schedule of assets and liabilities measured at fair value [Line Items]
Short-term investment	180,225	264,449
Derivative liability
Fair Value Measurements Using Significant other observable inputs (Level 2) [Member]
Financial Instruments and Risk Management (Details) - Schedule of assets and liabilities measured at fair value [Line Items]
Short-term investment
Derivative liability		396,597
Fair Value Measurements Using Significant unobservable inputs (Level 3) [Member]
Financial Instruments and Risk Management (Details) - Schedule of assets and liabilities measured at fair value [Line Items]
Short-term investment
Derivative liability

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Details) - Schedule of foreign currency exchange risk on net working capital	3 Months Ended
	Jan. 31, 2023 CAD ($)
Schedule of Foreign Currency Exchange Risk on Net Working Capital [Abstract]
Cash	$ 4,491,696
Amounts receivable	161,758
Accounts payable and accrued liabilities	(888,123)
Due to related parties	(112,957)
Total foreign currency financial assets and liabilities	3,652,374
Impact of a 10% strengthening or weakening of foreign exchange rate	$ 365,237

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Details) - Schedule of foreign currency exchange risk on net working capital (Parentheticals)	3 Months Ended
	Jan. 31, 2023
Schedule of Foreign Currency Exchange Risk on Net Working Capital [Abstract]
Impact of a strengthening or weakening of foreign exchange rate	10%

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Details) - Schedule of contractual maturities of financial liabilities - CAD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022
Total [Member]
Financial Instruments and Risk Management (Details) - Schedule of contractual maturities of financial liabilities [Line Items]
Accounts payable and accrued liabilities	$ 900,872	$ 1,906,706
Due to related parties	143,832	281,844
Derivative liability		396,597
Lease liability	27,017	52,399
Total	1,071,721	2,637,546
Within 1 year [Member]
Financial Instruments and Risk Management (Details) - Schedule of contractual maturities of financial liabilities [Line Items]
Accounts payable and accrued liabilities	900,872	1,906,706
Due to related parties	143,832	281,844
Derivative liability		396,597
Lease liability	27,017	52,399
Total	1,071,721	2,637,546
Within 2-5 years [Member]
Financial Instruments and Risk Management (Details) - Schedule of contractual maturities of financial liabilities [Line Items]
Accounts payable and accrued liabilities
Due to related parties
Lease liability
Total

Commitments (Details)

Commitments (Details)					1 Months Ended	3 Months Ended
	Mar. 01, 2022 CAD ($) shares	Mar. 01, 2022 ILS (₪) shares	Jan. 01, 2022 shares	Nov. 01, 2020 CAD ($) $ / shares shares	May 23, 2022 USD ($)	Jan. 31, 2023 CAD ($) shares	Jan. 31, 2021 CAD ($) shares	Jan. 01, 2023 CAD ($)	Mar. 14, 2022 USD ($)
Commitments (Details) [Line Items]
Monthly fee				$ 5,000
Share issued | shares				16,000
Listing date						3 years
Stock options granted | shares				16,000
Exercisable per share | $ / shares				$ 5.55
Share-based compensation						$ 30,280
Common shares issued | shares						2,667
Restricted stock unit | shares	666	666	666
Total shares | shares						26,000
Advisory agreement amount	$ 7,752	₪ 20,000
RSU’s equivalent									$ 10,000
Agreement amount								$ 5,000
Share-based compensation						$ 40,283
Restricted Stock Units					$ 10,000
Vested [Member]
Commitments (Details) [Line Items]
Share-based compensation						$ 6,549
Advisor [Member]
Commitments (Details) [Line Items]
Total shares | shares						6,774
Share-based compensation						$ 33,631
Restricted Stock Units [Member]
Commitments (Details) [Line Items]
Share-based compensation						$ 10,093
Total shares | shares						7,333
Commitments [Member]
Commitments (Details) [Line Items]
Listing date						3 years

Segmented Information (Details)

Segmented Information (Details)	3 Months Ended
	Jan. 31, 2023
Segmented Information [Abstract]
Operating segment	1

Segmented Information (Detail_2

Segmented Information (Details) - Schedule of company’s non-current assets by geographical location - CAD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022
Segmented Information (Details) - Schedule of company’s non-current assets by geographical location [Line Items]
Intangible assets	$ 173,840	$ 177,797
Property and equipment	15,012	17,610
Restricted cash	20,000	20,000
ROU asset	24,340	48,768
Deferred offering costs		270,768
Total	233,192	534,662
Canada [Member]
Segmented Information (Details) - Schedule of company’s non-current assets by geographical location [Line Items]
Intangible assets
Property and equipment
Restricted cash	20,000	20,000
ROU asset
Deferred offering costs
Total	20,000	20,000
United States [Member]
Segmented Information (Details) - Schedule of company’s non-current assets by geographical location [Line Items]
Intangible assets	52,152	53,339
Property and equipment
Restricted cash
ROU asset
Deferred offering costs		270,487
Total	52,152	323,826
Europe [Member]
Segmented Information (Details) - Schedule of company’s non-current assets by geographical location [Line Items]
Intangible assets	52,152	53,339
Property and equipment
Restricted cash
ROU asset
Deferred offering costs
Total	52,152	53,339
Asia [Member]
Segmented Information (Details) - Schedule of company’s non-current assets by geographical location [Line Items]
Intangible assets	69,536	71,119
Property and equipment	15,012	17,610
Restricted cash
ROU asset	24,340	48,768
Deferred offering costs
Total	$ 108,888	$ 137,497

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Feb. 22, 2023
Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Subsequent events, description	12,006 shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $141,071 at the time of issuance.